Dolat Capital: Suven Pharma Delivers Soft Q2, Growth Outlook Remains Intact

Nonetheless, Suven Pharma has reiterated its growth guidance for profit and revenue at 20% and 15%, respectively, in 2020-21.

Dolat Capital

02 Nov 2020, 11:30 AM IST

Tablets sits before packaging at a drug manufacturing unit in Kursk, Russia. (Photographer: Andrey Rudakov/Bloomberg)

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dolat Capital: Suven Pharma Delivers Soft Q2, Growth Outlook Remains Intact

Nonetheless, Suven Pharma has reiterated its growth guidance for profit and revenue at 20% and 15%, respectively, in 2020-21.

Choose a plan